The latest clinical studies indicate a drastic yo-yo effect in patients using modern weight loss injections. After discontinuing treatment, patients regain an average of 60 percent of lost body weight within just one year. Experts warn that without a permanent change in eating habits or lifelong use of the medication, the therapy results are not durable, which calls into question the long-term effectiveness of these expensive drugs.
Rapid weight regain
Patients regain an average of 60% of lost weight within the first year after stopping the medication, as confirmed by numerous clinical studies.
Necessity of lifelong therapy
Experts suggest that to maintain the effects, lifelong use of the preparations or a radical lifestyle change may be necessary.
Risk of yo-yo effect
The phenomenon of weight regain after pharmacological treatment is so common that the media have begun to call these drugs „yo-yo injections”.
The latest medical reports shed new light on the effectiveness of popular weight loss injections based on GLP-1 analogs. The results of published studies indicate that these drugs, while extremely effective during the active use phase, do not guarantee permanent effects after the end of treatment. The statistical data is relentless: within twelve months of stopping the medication, patients regain an average of two-thirds of the lost kilograms. This phenomenon, referred to as the „injection yo-yo”, is becoming the main challenge for modern dietetics and metabolic medicine. The mechanism of action of these drugs is based on mimicking satiety hormones, which leads to a significant reduction in appetite. However, after the active substance is eliminated from the body, the hunger center in the brain returns to its pre-therapy state, often with increased intensity. Experts emphasize that obesity is a chronic disease that requires either permanent pharmacotherapy or a radical and lasting lifestyle modification. Taking the medication alone without working on eating habits proves to be only a temporary solution, not a definitive cure for overweight. The first drugs from the GLP-1 receptor agonist group were approved for the treatment of type 2 diabetes as early as 2005, but their spectacular career as weight loss agents began only in the last decade. The medical debate now focuses on the question of the safety and rationale for lifelong use of these preparations. Although they help avoid complications related to obesity, such as hypertension or diabetes, their long-term impact on the body with years of use is not yet fully understood. An additional aspect is the economic barrier – the high cost of monthly treatment means many patients decide to discontinue therapy after reaching their desired weight, which almost immediately triggers the process of regaining weight. 60% — of lost weight returns within a year of stopping the medication Conclusions from the analysis of numerous press sources suggest that the pharmaceutical industry faces the necessity of developing new protocols for discontinuing treatment. Currently, there is a lack of clear guidelines on how to prevent a rapid increase in body weight after stopping the injections. Patients must be aware that pharmacology is only a supporting tool, not a magic solution that exempts them from caring about diet and physical activity in the long term.